Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Egetis Therapeutics, Audiocast, Q3'25

By Inderes11/25/2025, 9:00 AM
Egetis Therapeutics

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Nicklas Westerholm
00:00 - 18:14

Thank you, operator. Good morning, everyone, and a warm welcome to Egetis Therapeutics' Q3 results call, planned for the next 30 minutes. For those who haven't had the privilege to meet me before, I'm Nicklas Westerholm, the CEO of the company. With me today, I also have Yilmaz Mahshid, Chief Financial Officer; Henrik Krook, Vice President, Commercial Operations; Karl Hård, Vice President, Investor Relations; and Christian Sonesson, Vice President, Product Strategy and Development. So let's turn our attention to the topics that will be covered today. I am very pleased with the great progress made during the quarter and after the period, among other achievements. The FDA awarded us a Breakthrough Therapy Designation for Tiratricol on the 14th of July this year. We had a very successful pre-NDA meeting on October 21st with the FDA, with the agreement that Egetis can submit the NDA for Emcitate based on currently available data. Subsequently, we completed the ReTRIACt study of Emcitate and announced positive results, which leads to us being able to commence a rolling NDA submission in December this year. Furthermore, we will also cover the commercialization in Europe and launch preparations in the US, as well as provide a financial update, leaving ample time for questions. Let's begin with the Breakthrough Therapy Designation granted by the FDA on July 14th. In the first quarter of 2025, we received the entire data set from the Erasmus Medical Center, also called EMC, in Rotterdam, containing survival data from more than 600 patients with MCT8 deficiency. Approximately one-third of the patients had been treated with tiratricol, while two-thirds had not. We submitted a Breakthrough Therapy Designation application based on our own detailed analysis of the survival data, which confirmed a significant and substantial improvement in survival in tiratricol-treated patients. The breakthrough designation underscores both the urgent need for an effective treatment for patients with MCT8 deficiency and the clinically meaningful evidence demonstrated today. Tiratricol receiving a breakthrough designation this late in the clinical development program is, of course, very encouraging for the forthcoming NDA process, as these designations are typically awarded at an early stage in development. Let's now focus on the outcome of the Pre-NDA meeting with the FDA. The objective of today's meeting was to seek FDA advice and agreement on the overall content to support our New Drug Application for Emcitate in the US, with a special focus on the clinical data package, including the role and position of the ReTRIACt study. Importantly, and as agreed with the FDA, the NDA for Emcitate will be based on currently available clinical data. Furthermore, the ReTRIACt study is no longer considered pivotal for the NDA, unlike when the study was initially designed. FDA agreed that in the NDA submission, data from the ReTRIACt study will complement the existing data package from the EMC Survival Study and other clinical components. The FDA also recommended that the statistical analysis plan be revised. The SAP for the trial should be revised, recognizing that MCT8 deficiency is an ultra-rare condition. We have an unusually large and robust clinical data set from six different sources. This includes Triac Trial One with 46 patients. Triac Trial two involved 22 patients. The ReTRIACt study with 15 patients. The EMC cohort study includes 67 patients, and the EMC Survival Study involves over 600 patients. Furthermore, we also reached an agreement with the FDA that we can commence a rolling NDA submission in December 2025, targeting a complete NDA submission in early 2026, and anticipating completion of the FDA review process in the third quarter of 2026. We expect a priority review. So, in summary, as I'm sure you all appreciate, we are very pleased with the outcome of the meeting and the clear path to an NDA submission for Emcitate in the US, based on currently available clinical data. Let's now turn our attention to the positive outcome of the ReTRIACt study. On the 14th of November, we issued a press release announcing positive topline results from the ReTRIACt study with Emcitate, based on the comments from the FDA at the NDA meeting. The statistical analysis plan of the ReTRIACt study was revised with the intention to conclude the study prematurely. The revised SAP focuses on more efficient use of the data collected during the randomized treatment period, or RTP, using all T3 data, not only the binary information on rescue yes or no. That's why we consider the rate of change in T3 during the RTP, using all patient data on T3 collected to increase the statistical power of the study. Subsequently, a primary endpoint evaluating the rate of change in T3 during the RTP was added to the previously described primary endpoint based on T3 rescue criteria. From here on, referred to as primary endpoint two, Type I error is controlled via alpha recycling, testing primary endpoint one first, and if primary endpoint one is met, primary endpoint two will then be tested. The revised statistical plan was submitted to the FDA before database lock and unblinding of the ReTRIACt study, and as announced, the positive top-line results demonstrate a statistically significant difference in the rate of change in T3 in patients randomized to placebo versus patients continuing on tiratricol with a p-value of 0.034. And if you furthermore look at the results depicted here on the slide, what you see depicted to the left is the ranking of patients according to their change in T3 during the 30-day randomized treatment period. Displayed with a dashed line is the line of no change from the baseline. Hence, the patients with the largest increase in T3 during the RTP are at the top of the figure, and the patients with the largest decrease are at the bottom of the figure. What we observed regarding T3 movements is exactly what we expected; when withdrawing Tiratricol, the T3 levels in all placebo patients increase, but not much changes across the entire group. In fact, there is a complete separation between the two groups, with all patients randomized to placebo experiencing a larger increase in T3 compared to all seven patients randomized to Tiratricol. So what does this really tell us? And what does this mean for the results on the primary endpoint? On the right-hand side, the upper table shows the results for primary endpoint one. The rate of change in T3 during the RTP. For the placebo group, the T3 rate of change was 1.59, which means a 59 percent increase in T3 over 30 days. Whereas there was essentially no change for the tiratricol group, there was a statistically significant difference between placebo and tiratricol, expressed here as the ratio of the T3 rate of change, which was 1.494, with a p-value equal to 0.034. In the lower table, you can see the results for primary endpoint two: patients randomized to placebo met the rescue criterion, and no patients randomized to tiratricol met the rescue criterion. One patient randomized to tiratricol discontinued during the RTP. This discontinuation was not drug-related, and the patient is marked with a D in the left-hand figure. As you can see, there was no change in T3 during the RTP. However, as per the SAP, this patient was still imputed as a rescue for the analysis of primary endpoint two, leading to a four placebo versus one tiratricol comparison for primary endpoint two, which is not statistically significant. However, the sensitivity analysis below only considered the observed cases of rescue, leading to a comparison of four patients meeting the rescue criteria on placebo versus zero patients randomized to Tiratricol with a p-value of 0.070. Although not shown on this slide, after the RTP was completed, patients randomized to placebo reinitiated tiratricol treatment, and they all showed an expected decrease in T3 levels in the follow-up period. So to conclude, we are very pleased with the outcome from the pre-NDA meeting with the FDA and subsequently the positive ReTRIACt study outcome. As previously communicated, we now plan to submit an NDA for Emcitate with the currently available clinical data. We have a very robust data set for such a rare disorder, including data from the trials previously mentioned, and this could be visible here on the slide. Our plan is to commence a rolling submission in December 2025, targeting a complete NDA submission in early 2026, with an update and an anticipated completion of the FDA review process in the third quarter of 2026. With that, I will hand over to Henrik for an update on commercialization in Europe and the launch preparations in the US. Thank you, Nicklas, and good morning, everyone. I would like to start by giving a reminder and an update on our commercialization strategy. So we plan to commercialize Emcitate (tiratricol) through our team in Europe and the US. For other regions, we intend to collaborate with partner companies to ensure broad access to Emcitate® for patients. We have started executing this strategy by initiating the commercialization of Emcitate in Europe and beginning market preparations in the United States for the rest of the world. We have a license deal with Fujimoto for the development and commercialization in Japan. In June, we announced our first distribution deal, an agreement with Er-Kim for Turkey. I'm very pleased with how this collaboration is working. The Er-Kim team is in dialogue with several physicians and payers regarding the funding of Emcitate for identified patients. In October, we announced our second distribution deal, an agreement with Taiba to enable Emcitate access and named patient sales in the Gulf region. Initially Saudi Arabia, United Arab Emirates, Qatar, Oman, and Bahrain, and the ambition is to extend to more countries over time. So all in all, we continue to deliver on our commercialization strategy with our focus on reaching patients with urgent unmet medical needs. As we continue to execute our European commercialization strategy, I'm pleased to report steady progress across key markets with pricing and reimbursement processes moving forward in parallel. In Germany, we have successfully transitioned all managed access patients to the commercial Emcitate product. Our ongoing dialogues with physicians are delivering greater awareness of MCT8 deficiency, resulting in new patient identifications and treatment initiations. In France, our first reimbursement submission was rejected in September by the French Health Authority. This is not uncommon when it comes to orphan drugs in France, since the authority ideally would like to see randomized controlled data. We are now preparing a resubmission in early 2026 to address the payer objections, and will then include newly available data, such as the recently announced positive, placebo-controlled data from the ReTRIACt study. In this process, in addition to new data, we also have strong support from physicians who already have patients on Emcitate treatment. In Italy, the pricing and reimbursement process is underway, and commercial product is now available to patients. The pricing and reimbursement process is underway, and the commercial product is now available to patients in Spain. We recently held a successful advisory board with physicians and have secured support to generate local data to optimize our upcoming pricing and reimbursement submission. Beyond our core European markets, we are actively utilizing alternative funding pathways to facilitate named patient sales in additional countries. To date, this approach has enabled us to successfully provide Emcitate to patients in Poland, Austria, and Switzerland. Overall, we are delivering tangible results by expanding patient access and building momentum for Emcitate across Europe. Let me also walk through our US pre-launch progress, where we continue to execute with strong discipline. We have made significant strides in expanding our reach among healthcare providers and accelerating the diagnostic pathway for MCT8 deficiency. We have increased our engagements in endocrinology, genetics, and neurology with enhanced diagnostic considerations for MCT8 deficiency. Our partnerships with key opinion leaders and patient advocacy groups remain vital in raising awareness and supporting families. This momentum is translating into real impact, validating our awareness efforts. We are now aware of approximately 140 diagnosed patients in the US. Our Expanded Access Program is active at 15 sites, providing early access for eligible patients, generating valuable clinical insights, and building operational experience ahead of launch. On market access, we have advanced our readiness by engaging with payers and stakeholders, directly informing our launch pricing strategy, and strengthening our overall framework for distribution and patient services. Finally, we have recently added employees to our US organization, establishing core leadership and expanding our field medical capabilities to ensure the clinical community is prepared to diagnose and treat patients once Tiratricol is approved by the FDA. So in summary, we are executing our pre-launch strategy across four pillars: medical awareness and diagnostic acceleration, early access, market access readiness, and scalable launch infrastructure. With these foundations, we are confident in our ability to deliver a strong commercial launch and bring a transformative therapy to children and families living with MCT8 deficiency once regulatory approval is secured. With that, I would like to hand over to Yilmaz Mahshid for the financial update.

Yilmaz Mahshid
18:16 - 22:11

Thank you. Henrik. If you look at the financial slides, the revenue for the first nine months was 44.6 million Swedish kronor versus 35.3 million Swedish kronor in the same period last year. Revenue for the third quarter of the year was 17.4 million, compared to 9.4 million Swedish kronor in the same period last year, all of which is attributed to Emcitate. As mentioned in our half-year call, the gross profit margin is visibly lower than historical figures, both for the nine months and the third quarter. And it's worth reminding everyone again that the gross profit margin is visibly lower than historical figures for both the nine months and the third quarter. This goes back to the regulatory success we had with Emcitate in Europe and the commencement of the depreciation. As a consequence, the line item numbers not only include the recurring royalty payments to the founders of 3% and Erasmus Medical Center of 10%, but also non-recurring milestone payments of approximately 3.5 million Swedish kronor to Erasmus Medical Center, as well as 23.6 million Swedish kronor of intangible R&D. Depreciation. A reminder to listeners that the depreciation is a non-cash item, and it was initiated at the end of Q1 as a consequence of our approval in Europe. In an apples to apples year-over-year comparison, adjusting for the one-time payment and depreciation, adjusted gross profit is 35.3 million Swedish kronor for the first nine months. This marks an improvement not only in nominal terms but also in the gross margin level compared to the corresponding period. The Q3 operating results were nearly the same for the nine months, at -219.6 million versus 224.7 million Swedish kronor in the corresponding period. Results after tax for the nine months of the year were -222.8 million, versus -233.1 million Swedish kronor. The improvement versus prior corresponding periods is mainly driven by better cost control and the finance line items. Specifically, looking into the finance line items, you see the revaluation of the convertible, which fluctuates with the share price. The nine months 2025 figures for the revaluation were plus 6 million versus plus 3.1 million Swedish kronor. Remember that this is also a non-cash item. For the first nine months, cash flow from operating activities was almost completely the same, at -174.2 million versus -174.3 million Swedish kronor. Also, as you may have noticed, we continue to repay our debt and report 21.7 million Swedish kronor in repayment for the first nine months. This is an item which did not exist in the corresponding period. All in all, the cash flow for the first nine months was -200.6 million versus -176.2 million Swedish kronor. And the cash position in September 2025 was 145.7 million, versus 129.9 million Swedish kronor last year. So in the comparative period, we are in better shape, and it was gratifying to see that we strengthened the cash position further through the great support from our existing and new shareholders during the directed rights issue carried out after the close of the period on October 2nd. This resulted in a net cash injection to the company of 172 million Swedish kronor, which should be added on top of the reported cash position in the earnings release. With this, I hand back to Nick.

Henrik Krook
22:19 - 23:24

Thank you. And to conclude. Let's move on to the next slide, please. In essence, I think we are very pleased with the productive year we have had to date. We have delivered some historic milestones, such as Emcitate being approved in the European Union as the first and only approved treatment for the devastating condition of MCT8 deficiency, and subsequently launched it in Germany. We have signed two partnerships to expand access in Turkey and the Gulf region. We had a very successful Pre-NDA meeting following the Breakthrough Therapy Designation granted, leading to the NDA submission starting already this year. Even more exciting times are ahead of us, with a potential US approval and launch for Emcitate once more. As the first and only approved therapy for MCT8 deficiency in the US. So with that, operator, please go ahead, and we'll take some questions.

Operator
23:25 - 23:43

If you wish to ask a question, please dial the pound key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the Pound Key on your telephone keypad. The next question comes from Susannah Quek from Handelsbanken. Please go ahead.

Nicklas Westerholm
23:54 - 23:54

Hello.

Henrik Krook
23:55 - 23:56

Hi, Susanna.

Susannah Quek
23:57 - 24:21

Hi. Great. I'd like to start with two questions. So, first, a question on the ReTRIACt study. Trial? I'd like to follow up on the comments you received from the FDA regarding what changes they wanted in the statistical analysis. Could you perhaps expand on that to start off with?

Henrik Krook
24:21 - 25:37

Yes. No, as you know, we had a very constructive and positive dialogue with the FDA. I really need to commend their collaborative spirit. As you remember, the primary objective of the ReTRIACt study has been to confirm the effect on T3 seen in other clinical studies, as attributed to Tiratricol, which is why the ReTRIACt study was placebo-controlled. And in the discussion we had with the FDA, with their agreement to submit using the currently available data and the subsequent intention to close down the ReTRIACt study immediately, we considered with the FDA if there would be a more efficient use of the data collected during the randomized treatment period, i.e. By using all T3 data collected and not just the information on whether rescue was needed, which is inherently binary. That's why we either changed or added the primary endpoint as a rate of change in T3 over the randomized treatment period, using all patient data on T3 collected, to increase the statistical power. Christian, do you have anything to add from your perspective?

Christian Sonesson
25:39 - 26:07

I think you articulated that very well, Nicklas. I think it was very good and clear guidance from the FDA at the meeting, which led us to amend the SAP accordingly. And just as you say, we targeted the most efficient endpoint and promoted that to primary endpoint one. And, while at the same time, we are of course keeping the original primary endpoint in the study as well.

Susannah Quek
26:12 - 26:34

Understood. So, in terms of the rescue part of the trial, four patients required rescuing while four did not. How do you perceive this? Do you think that the one-month period was insufficient, or what is your interpretation of that?

Henrik Krook
26:36 - 27:10

Maybe I can start, Christian, and you can add. Of course, we are in the process of still analyzing all the data. What we see is, as I mentioned before, a clear separation between the two groups. All eight patients randomized to placebo experienced a larger increase in T3 compared to the seven patients randomized to Tiratricol. So what we actually observe on T3 movements is exactly what we expected. Christian, anything to add from your perspective?

Christian Sonesson
27:11 - 28:09

I think that, based on what we see on the primary endpoint one, we observe a 59% increase in the placebo group over 30 days. We have more or less stable treatment T3 levels. So it's really a question of time before you would have all the placebo patients hitting the rescue criteria. And I think it becomes a little bit about the interplay between where you set the rescue criteria versus how much time you have. I think that the results on the primary endpoint one strongly suggest that if we had continued the trial for just a little bit longer, you would have seen all placebo patients rescued.

Henrik Krook
28:10 - 28:56

Thank you. Christian. And then really, to summarize, one should also take a step back. We have an unusually large and robust data set. Again Susanna, coming back to the number of studies and the number of patients we have in this ultra-rare condition, everything is pointing in the right direction. And most importantly, obviously recognizing the survival benefits we have seen in patients treated with tiratricol versus untreated patients. And subsequently, the productive discussion with the FDA confirmed that we are moving forward, and the agency agreed to the submission based on currently available data. Maybe we should move to the next question. Thank you so much for your questions.

Susannah Quek
28:57 - 28:58

Thank you.

Operator
29:03 - 29:08

The next question comes from Chiara Monteroni from Van Lanschot Kempen. Please go ahead.

Chiara Monteroni
29:10 - 29:29

Hello. Thank you for taking my question. To start off, I need a clarification. So you mentioned that all patients on placebo restarted tiratricol, and the T3 levels decreased again. Do you mean all the patients on placebo or only the four that met the criterion?

Henrik Krook
29:31 - 29:42

I hope I understood the question correctly. I believe I'm repeating it back to you. You're referring to after the randomized treatment period. Correct?

Chiara Monteroni
29:42 - 29:43

Correct?

Henrik Krook
29:43 - 30:08

Yes. Yes. So, yes. You're absolutely correct; it wasn't shown on the slide. But after the randomized treatment period was completed, patients that were randomized to placebo reinitiated Emcitate treatment and they all showed, as expected, a decrease in T3 levels in the so-called follow-up period. So yes, you're correct.

Chiara Monteroni
30:10 - 30:12

So all eight.

Henrik Krook
30:12 - 30:13

Yes. Correct.

Chiara Monteroni
30:14 - 30:26

Okay, great. And then, a second question, if I may, could you give us a sense of how much establishing the US commercialization force will weigh on your spending?

Henrik Krook
30:28 - 31:33

Well, we don't give guidance on cash burn rate and investment levels, but we are trying to triangulate this because obviously it's important, right? The US will be the most important market for Emcitate as it is for many other companies. So, of course, we'll make sure that we have sufficient investments moving forward. Ahead of the launch and through the launch in the second half of 2026, you will see an increase in investments in the commercial and medical affairs infrastructure in the US. However, that will be offset by decreased R&D costs since we are now closing down the ReTRIACt study and to calibrate a bit on the size of the infrastructure, we envisage being around 25 FTEs at the point of launch. We have started to build that up already now in the second half of 2025. And we'll do more of that in the first half of 2026.

Chiara Monteroni
31:36 - 31:37

Okay. Thank you.

Henrik Krook
31:38 - 31:39

Thank you, Chiara.

Operator
31:43 - 31:47

The next question comes from Frederik Thor from Redeye. Please go ahead.

Frederik Thor
31:49 - 32:07

Hello and thank you. My question was about your mention that all German patients on early access have been converted. How well is that reflected in the sales for the quarter? I mean, how early in the quarter were all converted and so on? Can you provide us with more details on that?

Henrik Krook
32:08 - 32:41

Well, I can start. And, Henrik, you can elaborate. And we'll do furthermore of that in the first half of 2026. So, obviously, we have mentioned this before. We don't give granular information on a patient-by-patient basis. We had converted the majority of the patients in quarter two. We also had a few conversions in quarter three. More importantly, as Henrik mentioned, we have also identified additional patients who have now been prescribed treatment. So it's a work in progress, but it's definitely moving in the right direction.

Frederik Thor
32:44 - 32:59

Got it. And the final question about the process in France. Could you provide some details on the timeline there? What is the best hope for getting an approved reimbursement in France?

Nicklas Westerholm
33:00 - 34:10

Yeah. Henrik Krook is happy to answer that. So, first of all, I would like to emphasize that it is not uncommon for the reimbursement submission to initially be rejected in France. Since the ideal scenario would involve having randomized controlled data. So we are now preparing for the resubmission early 2026 to address their objections. And we will then include the new data available. And that includes, of course, both the positive pre-trial data and more survival data. And then, this process is expected to take 1 to 2 years, which is typically the case in France. Overall, in our resubmission, it will consist of a much stronger data package. Therefore, we see a much higher likelihood of getting reimbursed in France.

Frederik Thor
34:13 - 34:15

Got it. Thank you. That's all from me.

Henrik Krook
34:15 - 34:39

Thank you, Frederic. And with that, we recognize that we're running over time. So with that, we need to close down and thank the audience for their participation and wish everybody a great rest of the day. And we are looking forward to an exciting 2026. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…